Alessandra Benenati

Mrs. Alessandra Benenati

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
Maria Grazia MaggioMaria Grazia Maggio
Maria Grazia Maggio
MBMirjam Bonanno
Mirjam Bonanno
ACAndrea Calderone
Andrea Calderone
Amelia RizzoAmelia Rizzo
Amelia Rizzo
NBNebahat Bulut
Nebahat Bulut
Rocco Salvatore Salvatore CalabròRocco Salvatore Salvatore Calabrò
Rocco Salvatore Salvatore Calabrò
Background: Chronic neuropathic pain (CNP) is a common consequence of neurological conditions such as spinal cord injury (SCI), complex regional pain syndrome (CRPS), and phantom limb pain (PLP). These conditions are often associated with distorted body representation (BR) and altered sensory processing. Virtual reality (VR) offers immersive, multisensory experiences that can modulate attention, recalibrate BR, and potentially alleviate pain. Objective: This systematic review aims to synthesize evidence on the use of VR-based interventions for managing CNP in patients with neurological conditions. It explores how VR can influence pain perception through body remapping. Furthermore, this review seeks to identify gaps in current research, offering recommendations for future research directions and clinical applications. Methods: We performed a comprehensive literature search in PubMed, Web of Science, and Scopus for studies published between January 2014 and December 2024. We included original studies that examined VR interventions in patients with neurological conditions and CNP, assessing pain reduction, improvements in BR, or functional recovery. We excluded reviews, animal model studies, migraine-related studies, and those lacking a clear VR intervention or relevant clinical outcome data. The quality of the included studies was evaluated using the revised Cochrane Risk of Bias Tool for Randomized Trials and the Cochrane Risk of Bias in Nonrandomized Studies of Interventions tool. Given the heterogeneity in study design, VR protocols, and outcome measures, a qualitative synthesis approach was adopted based on the synthesis without meta-analysis framework. Results: Ten studies—both randomized controlled trials and uncontrolled experimental designs—met the inclusion criteria. These studies focused on the application of VR in SCI (n=4, 40%), CRPS (n=4, 40%), and PLP (n=2, 20%), using interventions such as immersive VR, mirror visual feedback, visuotactile stimulation, and virtual body illusions. Sample sizes ranged from 9 to 70 participants, with varying degrees of neurological impairment. Most of the studies (n=7, 70%) reported substantial reductions in pain intensity and improvements in embodiment and perceived body ownership. In SCI, combining VR with neuromodulation techniques enhanced analgesic effects. In CRPS, modifying the visual appearance of the affected limb improved body image and decreased pain perception. In PLP, kinesthetic and visual feedback delivered through VR environments significantly reduced PLP and improved movement representation. Conclusions: Overall, the quality of evidence ranged from moderate to low, mainly due to small sample sizes, protocol heterogeneity, and risk of bias. Evidence regarding adherence to VR therapy was particularly limited. Nonetheless, VR shows strong potential as a noninvasive, patient-tailored therapeutic tool for CNP. VR could provide innovative and engaging strategies to reduce pain and enhance functional outcomes in populations with neurological conditions. Future research should focus on developing standardized protocols and conducting large-scale, high-quality trials to validate VR’s long-term efficacy and integration into routine clinical practice. Trial Registration: PROSPERO CRD42024606150; https://www.crd.york.ac.uk/PROSPERO/view/CRD42024606150

13 April 2021 in Behavioral Sciences
Verified
Journal Article
Open access
PDF file
Pasquale CaponnettoPasquale Caponnetto
Pasquale Caponnetto
ABAlessandra Benenati
Alessandra Benenati
Marilena MagliaMarilena Maglia
Marilena Maglia
The COVID-19 epidemic posed great challenges to the healthcare community. To contain the epidemiological emergency, confinement measures were instituted, affecting the entire population. The lack of social contact, as well as the disruption of daily life, caused the exacerbation of anxiety and depressive symptoms. The present review of the literature aims to investigate what the effects of the pandemic have been on patients with schizophrenia, hypothesizing, an exacerbation of psychotic symptomatology (positive, negative, disorganized symptoms). Between November 2020 and January 2021, 5353 articles were collected and analyzed from the databases of the ResearchGate, Pubmed, and Psycnet websites, subjected to PRISMA methodology. Of these, 11 were evaluated for eligibility, but only three were included in the study because they met all inclusion criteria. The research did not confirm the expected results, showing that any kind of worsening of schizophrenic symptomatology involved the study samples. However, interesting outcomes were highlighted, such as a significant increase in general well-being during the early period of the pandemic, especially by women, or an increase in CPR (C-reactive Protein) levels in the blood, signaling an inflammatory state. Although the systematic review refuted the initial hypothesis, this must be a starting point: the topic is recent and these findings leave ample room for further investigation, particularly in long-term longitudinal research. It is possible that the true response to this disruption of daily life that occurred only during the past year may manifest itself later in time. On the other hand, interesting outcomes have been brought to light that may provide further interesting research insights.

1 May 2025 in Digital Health
Verified
Journal Article
Open access
Maria Grazia MaggioMaria Grazia Maggio
Maria Grazia Maggio
Amelia RizzoAmelia Rizzo
Amelia Rizzo
ABAlessandra Benenati
Alessandra Benenati
FGFabio Mauro Giambò
Fabio Mauro Giambò
ACAntonino Cannavò
Antonino Cannavò
Rocco Salvatore Salvatore CalabròRocco Salvatore Salvatore Calabrò
Rocco Salvatore Salvatore Calabrò
Objective: Parkinson's disease (PD) is a progressive neurodegenerative disorder that not only impairs motor functions but also may lead to significant cognitive decline, greatly affecting the quality of life for both patients and their caregivers. This study aims to evaluate the feasibility and potential effectiveness of cognitive tele-rehabilitation (TR) plus virtual reality (VR), compared to traditional home-based rehabilitation methods, focusing on cognitive outcomes, quality of life, usability, and the impact on caregiver strain in patients with PD. Methods: In this pilot randomized controlled trial, 20 PD patients and their primary caregivers were randomly assigned to either a control group (CG) receiving traditional cognitive training or an experimental group (EG) undergoing cognitive TR using a VR rehabilitation system, with assessments conducted before and after the 8-week intervention. Results: TR was rated as highly usable (System Usability Scale mean score: 84.3 ± 9.5). Post-intervention analyses showed significant improvements in global cognitive functioning (Montreal Cognitive Assessment (MoCA): p = 0.002) and quality of life (Parkinson's Disease Questionnaire (PDQ)-8: p = 0.002) in the EG. The CG also showed improvements in MoCA ( p = 0.008) and PDQ-8 ( p = 0.016), although to a lesser extent than the EG. A reduction in caregiver burden was observed in both groups but did not reach statistical significance. Analysis of Δ scores revealed a significantly greater MoCA improvement in the EG compared to the CG ( p = 0.019). Statistically significant differences were found between the groups in the Family Strain Questionnaire and PDQ-8 Δ scores. Conclusion: These findings suggest that cognitive TR, particularly when integrated with VR, might be useful in improving cognitive function and quality of life in PD patients and could play a key role in future PD management strategies, potentially easing the burden on caregivers.

5 December 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Maria Grazia MaggioMaria Grazia Maggio
Maria Grazia Maggio
ABAlessandra Benenati
Alessandra Benenati
FIFederica Impellizzeri
Federica Impellizzeri
Amelia RizzoAmelia Rizzo
Amelia Rizzo
MBMartina Barbera
Martina Barbera
Rocco Salvatore Salvatore CalabròRocco Salvatore Salvatore Calabrò
Rocco Salvatore Salvatore Calabrò
Background and aim: While conventional MS rehabilitation primarily addresses physical and cognitive symptoms, recent advances in VR technology offer immersive environments that facilitate both emotional and cognitive skill development. The purpose of this study is to evaluate the impact of VR-based training on emotional self-efficacy in multiple sclerosis (MS) patients and examine its association with cognitive function improvement. Additionally, this study aims to explore potential gender differences in these outcomes, hypothesizing that gender may influence the effectiveness of VR-based rehabilitation, which could inform more tailored approaches for emotional and cognitive rehabilitation in MS. Method: The present retrospective study analyzed data from 43 MS patients undergoing cognitive and behavioral rehabilitation at the IRCCS Centro Neurolesi “Bonino Pulejo” in Italy, comparing a VR intervention group (VR-G) and a control group receiving traditional rehabilitation. Emotional self-efficacy, depression, and anxiety were assessed, alongside cognitive function pre- and post-intervention. Results: Findings indicate that the VR-G showed significant improvements in managing negative emotions, reduced depressive and anxiety symptoms, and enhanced cognitive performance, particularly in verbal learning and working memory. Gender-based analysis revealed a trend suggesting that females in the VR-G may exhibit greater improvements in positive emotional self-efficacy, although this difference did not reach statistical significance. Spearman’s correlation highlighted associations between emotional self-efficacy and cognitive gains, supporting the potential of VR to foster both emotional and cognitive resilience. Conclusions: These findings suggest that VR training may provide a tailored approach for MS rehabilitation, enhancing therapeutic outcomes by integrating emotional and cognitive training in an immersive setting. Further research should investigate long-term effects and neurophysiological correlates of VR training to optimize MS rehabilitation.

9 January 2025 in JMIR Preprints
Verified
Preprint
Open access
Maria Grazia MaggioMaria Grazia Maggio
Maria Grazia Maggio
MBMirjam Bonanno
Mirjam Bonanno
ACAndrea Calderone
Andrea Calderone
Amelia RizzoAmelia Rizzo
Amelia Rizzo
NBNebahat Bulut
Nebahat Bulut
Rocco Salvatore Salvatore CalabròRocco Salvatore Salvatore Calabrò
Rocco Salvatore Salvatore Calabrò
BACKGROUND Chronic neuropathic pain (CNP) is a common consequence of neurological conditions such as spinal cord injury (SCI), complex regional pain syndrome (CRPS), and phantom limb pain (PLP). These conditions are often associated with distorted body representation (BR) and altered sensory processing. Virtual reality (VR) offers immersive, multisensory experiences that can modulate attention, recalibrate BR, and potentially alleviate pain. OBJECTIVE This systematic review aims to synthesize evidence on the use of VR-based interventions for managing CNP in patients with neurological conditions. It explores how VR can influence pain perception through body remapping. Furthermore, this review seeks to identify gaps in current research, offering recommendations for future research directions and clinical applications. METHODS We performed a comprehensive literature search in PubMed, Web of Science, and Scopus for studies published between January 2014 and December 2024. We included original studies that examined VR interventions in patients with neurological conditions and CNP, assessing pain reduction, improvements in BR, or functional recovery. We excluded reviews, animal model studies, migraine-related studies, and those lacking a clear VR intervention or relevant clinical outcome data. The quality of the included studies was evaluated using the revised Cochrane Risk of Bias Tool for Randomized Trials and the Cochrane Risk of Bias in Nonrandomized Studies of Interventions tool. Given the heterogeneity in study design, VR protocols, and outcome measures, a qualitative synthesis approach was adopted based on the synthesis without meta-analysis framework. RESULTS Ten studies—both randomized controlled trials and uncontrolled experimental designs—met the inclusion criteria. These studies focused on the application of VR in SCI (n=4, 40%), CRPS (n=4, 40%), and PLP (n=2, 20%), using interventions such as immersive VR, mirror visual feedback, visuotactile stimulation, and virtual body illusions. Sample sizes ranged from 9 to 70 participants, with varying degrees of neurological impairment. Most of the studies (n=7, 70%) reported substantial reductions in pain intensity and improvements in embodiment and perceived body ownership. In SCI, combining VR with neuromodulation techniques enhanced analgesic effects. In CRPS, modifying the visual appearance of the affected limb improved body image and decreased pain perception. In PLP, kinesthetic and visual feedback delivered through VR environments significantly reduced PLP and improved movement representation. CONCLUSIONS Overall, the quality of evidence ranged from moderate to low, mainly due to small sample sizes, protocol heterogeneity, and risk of bias. Evidence regarding adherence to VR therapy was particularly limited. Nonetheless, VR shows strong potential as a noninvasive, patient-tailored therapeutic tool for CNP. VR could provide innovative and engaging strategies to reduce pain and enhance functional outcomes in populations with neurological conditions. Future research should focus on developing standardized protocols and conducting large-scale, high-quality trials to validate VR’s long-term efficacy and integration into routine clinical practice. CLINICALTRIAL PROSPERO CRD42024606150; https://www.crd.york.ac.uk/PROSPERO/view/CRD42024606150